TOTAL: $57.375M

Year to Date: $467.05M

Company (Symbol)#*

Partner (Country)

Amt. (M)

Triggering Event

Details (Date)

Ablynx* (Belgium)

Procter & Gamble Co.


Milestone payment

Ablynx received payment for the discovery of Nanobodies against a second target for possible new treatments in the musculoskeletal area (6/18)

Albany Molecular Research Inc. (AMRI)

Bristol-Myers Squibb Co.


Milestone payment

Albany molecular received the payment for proceeding into preclinical development with a compound to treat depression and diseases of the central nervous system (6/11)

A.P. Pharma Inc.*

Paul Royalty Fund affiliate


Milestone payment

The payment is in connection to the company's October agreement to sell its royalty rights to dermatology products Regin-A Micro and Carac (6/7)

Applied Genetic Technologies Corp.*

Genzyme Corp. (GENZ)


Milestone payment

Applied Genetic received the payment for its successful transfer of its adeno-associated virus vector production technology (6/21)

Bacilligen Inc.*

Maryland Department of Business and Economic Development



Bacilligen received a $50,000 investment from Maryland's Challenge Investment Program fund to advance the company's three technology platforms (6/26)

Eurand NV (Italy; EURX)

GlaxoSmithKline plc (UK)


Milestone payment

Eurand received $1M from GSK, which started a registration bioequivalence study for a new orally disintegrating tablet formulation of an undisclosed compound (6/5)

Genmab A/S (Denmark; CSE:GEN)

GlaxoSmithKline plc (UK)


Milestone payment

Genmab received the payment for reporting positive efficacy results in a Phase II study in rheumatoid arthritis (6/26)

Immunotope Inc.*

Ben Franklin Technology Partners of Southeastern PA



Immunotrope received the money to fund its Phase I IMT-1012 immunotherapeutic vaccine trial (6/26)

Noven Pharmaceuticals Inc. (NOVN)

Shire plc (UK)


Milestone payment

Noven received a $5.9M payment after Shire exercised an option to acquire exclusive development rights to a new transdermal patch for ADHD to be formulated by Noven (6/20)

Pharmacopeia Drug Discovery Inc. (PCOP)

GlaxoSmithKline plc (UK)


Milestone payment

Pharmacopeia received the payment in connection with a March 2006 collaboration; it was triggered by Pharmacopeia's completion of certain early discovery activities (6/13)

Proteros Biostructures GmbH* (Germany)

Bayer HealthCare AG (Germany)


Milestone payment

Proteros is due a payment for the progress in its collaboration with Bayer in the field of fragment-based protein crystallography (6/20)

Renovis Inc. (RNVS)

Pfizer Inc.


Milestone payments

Renovis received the payments as part of its research collaboration with Pfizer to develop vanilloid receptor 1 antagonists for treating pain and other conditions (6/8)

Sunesis Pharmaceuticals Inc. (SNSS)

SARcode Corp.


Milestone payment

Sunesis earned a $375,000 convertible note from SARcode for the latter's selection of an LFA-1 inhibitor development candidate and the commencement of GLP toxicology studies (6/5)

Transgene SA (France; FSE:TGNA)

F. Hoffmann-La Roche Ltd. (Switzerland)


Milestone payment

Transgene received the payment for the U.S. and European regulatory authorities' reviews of Phase III plans for TG 4001/R3484 (MVA-HPV-IL-2) in high-grade cervical intraepithelial neoplasia (6/1)


# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Private company.

Currency conversions are based on exchange rates at the time of the deal.

ND = Not disclosed. FSE = Frankfurt Stock Exchange.